FDA Finds No Increased CVD Risk With Parkinson’s Drug
The U.S. Food and Drug Administration (FDA) issued an alert on Oct. 26 for the Parkinson’s drug entacapone, stating that an FDA safety review found no increase in cardiovascular risks for patients taking the drug. The recommendations found on the drug labels for Comtan (entacapone) and Stalevo (a combination of entacapone, carbidopa, and levodopa) will remain the same.
According to the alert, health care providers and patients should report any adverse events related to the use of entacapone to the FDA.
< Back to Listings